Marcis Bajars
About
Marcis Bajars is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Ecology.
According to data from OpenAlex, Marcis Bajars has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 5 papers in Ecology. Recurrent topics in Marcis Bajars's work include Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (11 papers) and Polyomavirus and related diseases (10 papers). Marcis Bajars is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (11 papers) and Polyomavirus and related diseases (10 papers). Marcis Bajars collaborates with scholars based in United States, Germany and France. Marcis Bajars's co-authors include Sandra P. D’Angelo, Célèste Lebbé, Patrick Terheyden, David R. Spigel, Barbara Ellers‐Lenz, Meliessa Hennessy, Howard L. Kaufman, Isabella Zwiener, Fabrice Barlési and Mary Ruisi and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer Research.
In The Last Decade
Marcis Bajars
32 papers receiving 1.1k citations
Hit Papers
Peers
Marcis Bajars
Ibrahima Soumaoro United States
Juan A. Santamaria‐Barria United States
Jill Ainslie Australia
Anne Tallet France
Francesca Trevisan Italy
Sandrine Mansard France
Michael G. E. OʼRourke Australia
Saad Akhtar Saudi Arabia
João Pedreira Duprat Neto Brazil
Citations per year, relative to Marcis Bajars Marcis Bajars (= 1×)
peers
Ibrahima Soumaoro
Countries citing papers authored by Marcis Bajars
Since
Specialization
Citations
This map shows the geographic impact of Marcis Bajars's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcis Bajars with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcis Bajars more than expected).
Fields of papers citing papers by Marcis Bajars
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marcis Bajars. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcis Bajars. The network helps show where Marcis Bajars may publish in the future.
Co-authorship network of co-authors of Marcis Bajars
This figure shows the co-authorship network connecting the top 25 collaborators of Marcis Bajars. A scholar is included among the top collaborators of Marcis Bajars based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcis Bajars. Marcis Bajars is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lim, Ho Yeong, Jeong Heo, Baek‐Yeol Ryoo, et al.. (2024). Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC. Hepatology. 81(1). 32–43.
2.
Ferris, Robert L., Hisham Mehanna, Jonathan D. Schoenfeld, et al.. (2024). XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-risk, Cisplatin-ineligible Patients with Resected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN). International Journal of Radiation Oncology*Biology*Physics. 118(5). e17–e18.
3.
Birrer, Michael J., Guiling Li, Mayu Yunokawa, et al.. (2024). Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure. JAMA Oncology. 10(9). 1204–1204.
4.
Ferris, Robert L., Hisham Mehanna, Jonathan D. Schoenfeld, et al.. (2024). Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future Oncology. 20(12). 739–748.
5.
Ferris, Robert L., Hisham Mehanna, Jonathan D. Schoenfeld, et al.. (2023). XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).. Journal of Clinical Oncology. 41(16_suppl). TPS6101–TPS6101.
6.
Haddad, Robert I., Kevin J. Harrington, Makoto Tahara, et al.. (2023). Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?. Cancer Treatment Reviews. 119. 102585–102585.
7.
Yoo, Changhoon, Milind Javle, Filippo de Braud, et al.. (2023). Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology. 78(3). 758–770.
8.
Manitz, Juliane, Sandra P. D’Angelo, Andrea B. Apolo, et al.. (2022). Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. Journal for ImmunoTherapy of Cancer. 10(2). e003302–e003302.
9.
Gulley, James L., Mario E. Lacouture, Alexander I. Spira, et al.. (2021). 1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials. Annals of Oncology. 32. S1181–S1182.
10.
Park, Keunchil, Mustafa Özgüroğlu, Johan Vansteenkiste, et al.. (2021). Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Journal of Thoracic Oncology. 16(8). 1369–1378.
11.
Park, Keunchil, Mustafa Özgüroğlu, Johan Vansteenkiste, et al.. (2021). Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. Lung Cancer. 154. 92–98.
12.
Verschraegen, Claire F., Guy Jérusalem, Edward F. McClay, et al.. (2020). Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. Journal for ImmunoTherapy of Cancer. 8(2). e001064–e001064.
13.
Vaishampayan, Ulka N., Patrick Schöffski, Alain Ravaud, et al.. (2019). Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. Journal for ImmunoTherapy of Cancer. 7(1). 275–275.
14.
Barlési, Fabrice, Mustafa Özgüroğlu, Johan Vansteenkiste, et al.. (2019). Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC). Annals of Oncology. 30. v611–v612.
15.
Barlési, Fabrice, Johan Vansteenkiste, David R. Spigel, et al.. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. The Lancet Oncology. 19(11). 1468–1479.
16.
Barlési, Fabrice, Johan Vansteenkiste, David R. Spigel, et al.. (2018). OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial. Journal of Thoracic Oncology. 13(10). S331–S332.
17.
D’Angelo, Sandra P., Jeffery S. Russell, J.C. Hassel, et al.. (2017). Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC). Annals of Oncology. 28. v435–v436.
18.
D’Angelo, Sandra P., Jeffrey S. Russell, Jessica C. Hassel, et al.. (2017). First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.. Journal of Clinical Oncology. 35(15_suppl). 9530–9530.
19.
Kelly, Karen, J. R. Infante, Nicholas Iannotti, et al.. (2016). Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial. Open Repository and Bibliography (University of Liège).
20.
Kelly, Karen, Manish R. Patel, Jeffrey R. Infante, et al.. (2016). Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial. Cancer Research. 76(14_Supplement). CT132–CT132.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ibrahima Soumaoro Breakdown of academic impact, for papers by Juan A. Santamaria‐Barria Breakdown of academic impact, for papers by Jill Ainslie Breakdown of academic impact, for papers by Anne Tallet Breakdown of academic impact, for papers by Francesca Trevisan Breakdown of academic impact, for papers by Sandrine Mansard Breakdown of academic impact, for papers by Michael G. E. OʼRourke Breakdown of academic impact, for papers by Saad Akhtar Breakdown of academic impact, for papers by João Pedreira Duprat Neto Breakdown of academic impact, for papers by Elodie Miquelestorena‐Standley